Mobia Medical (NASDAQ:MOBI) Director Casey Tansey Purchases 35,572 Shares

Mobia Medical, Inc. (NASDAQ:MOBI) Director Casey Tansey acquired 35,572 shares of the business’s stock in a transaction dated Thursday, August 13th. The shares were bought at an average price of $11.51 per share, for a total transaction of $409,433.72. Following the acquisition, the director owned 268,904 shares of the company’s stock, valued at approximately $3,095,085.04. This represents a 15.25% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Mobia Medical Trading Down 0.1%

NASDAQ MOBI opened at $11.73 on Wednesday. The stock has a market capitalization of $390.49 million and a PE ratio of -0.61. The company has a current ratio of 13.28, a quick ratio of 12.80 and a debt-to-equity ratio of 0.04. The business has a fifty day moving average of $12.40. Mobia Medical, Inc. has a 12-month low of $10.19 and a 12-month high of $15.29.

Mobia Medical (NASDAQ:MOBI) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.27). The business had revenue of $13.51 million during the quarter. The business’s revenue for the quarter was up 102.4% compared to the same quarter last year. As a group, sell-side analysts forecast that Mobia Medical, Inc. will post -2.76 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MOBI. Weiss Ratings began coverage on shares of Mobia Medical in a report on Wednesday, August 12th. They issued a “sell (e-)” rating on the stock. JPMorgan Chase & Co. raised their target price on shares of Mobia Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. Wall Street Zen raised shares of Mobia Medical from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. Zacks Research raised Mobia Medical to a “hold” rating in a research report on Wednesday, June 3rd. Finally, Bank of America initiated coverage on Mobia Medical in a report on Tuesday, June 2nd. They issued a “buy” rating and a $16.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.75.

Mobia Medical Company Profile

Mobia Medical Inc is a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments. Mobia Medical Inc is based in AUSTIN, Texas.